No confirmation from GSK yet so it makes you wonder why they want to keep it a secret. Not newsworthy or price sensitive enough for them ????? I doubt it.
No further news on Simcere's licence either ??? As mentioned before we all know how big the Chinese market is so it just adds weight to hanging in there with BTA.
Techically its holding well with $2.00 been strongly tested and held so it's just a matter of sitting it out.
- Forums
- ASX - By Stock
- BTA
- relenza approved for sale in china
relenza approved for sale in china, page-13
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)